

## NPB References

### December 23/ January 24

---

Pg12 – CPD Immunity:

#### References

- <sup>1</sup> Schapowal A. Schweiz Z Ganzheitsmed 2011; 23: 40-44
- <sup>2</sup> Chicca A et al. Synergistic immunopharmacological effects of N-alkylamides in *Echinacea purpurea* herbal extracts. International immunopharmacology 2009; 9 (7-8): 850-858
- <sup>3</sup> Vimalanathan S et al. High-potency anti-influenza therapy by a combination of *Echinacea purpurea* fresh herb and root tinctures. Journal of Applied Science 2013; 3 (12): 001-005
- <sup>4</sup> Hudson J, Vimalanathan S. Pharmaceuticals 2011; 4: 1019-1031
- <sup>5</sup> Sharma SM et al. Phytomedicine 2010; 17 (8-9): 563-8
- <sup>6</sup> Vimalanathan S, et al. Prevention of influenza virus induced bacterial superinfection by standardized *Echinacea purpurea*, via regulation of surface receptor expression in human bronchial epithelial cells. Virus Research 2017; 233: 51-59
- <sup>7</sup> Signer, J. et al. In vitro virucidal activity of Echinaforce<sup>®</sup>, an *Echinacea purpurea* preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J 2020; 17: 136
- <sup>8</sup> Meeran MFN et al.. Heliyon 7 2021; e05990
- <sup>9</sup> Declerck K et al. *Echinacea purpurea* (L.) Moench treatment of monocytes promotes tonic interferon signaling, increased innate immunity gene expression and DNA repeat hypermethylated silencing of endogenous retroviral sequences. BMC Complement Med Ther. 2021; 21 (1): 141
- <sup>10</sup> Vimalanathan S et al. Microorganisms 2022; 10: 2145
- <sup>11</sup> Jawad M et al. Evidence-Based Complementary and Alternative Medicine 2012. Article ID 841315 doi: 10.1155/2012/841315
- <sup>12</sup> Weishaupt R et al. Dose-dependency of *Echinacea* in the treatment of acute common colds in children 4-12 years. Children 2020; 7: 292
- <sup>13</sup> Schapowal A. Wien Med Wochenschr. 2013; 163 (3-4): 102-5
- <sup>14</sup> Ardjomand-Woelkart K, Bauer R. Planta Med 2016; 82 (1-2): 17-31